TABLE 1.

Organoselenium compounds and their role in preventing obesity-associated breast cancer.

SI No	Name of the compound	Structure of the compound	Models used	Role in breast cancer	References
1	Selenomethionine		MCF-7 4T1.2 and female BALB/c mice	-Increases antioxidant enzymes and UCP2 protein expression, antioxidant damage reduction in lipid and proteins	Perou et al. (1999); Holliday and Speirs (2011); Chen et al. (2013)
				-Protection against breast cancer metastasis and tumor inhibition
2	Selenocysteine		MDA-MB-231, MDA-MB-436, and MDA-MB-468	-S-phase cell cycle arrest	Fernandes and Gandin (2015)
				-Apoptosis	Long et al. (2015)
3	Methylselenocysteine		TM6	-Inhibits cell growth by inhibiting the activity of PI3-K and its downstream effector molecules in mouse mammary tumor cells in vitro	Unni et al. (2005)
4	Ebselen		MCF-7, Zucker diabetic fatty (ZDF) rats	-Cancer prevention in combination with radiotherapy	Mahadevan et al. (2013); Thabet and Moustafa (2017); Dong et al. (2020)
				- Reduces the levels of fasting blood glucose
5	Methyl seleninic acid		MDA-MB-231, MDA-MB-157, and BT-549	-Enhances the anticancer efficacy of paclitaxel in triple-negative breast cancer. Growth inhibition of triple-negative BC	Qi et al. (2012); Qiu et al. (2019); Sánchez-Jiménez et al. (2019); Tan et al. (2019)
			SCID mice bearing MDA-MB-231 triple-negative breast cancer xenografts	-Cytotoxicity
			Mouse 4T1 cells	- Downregulation of PII and PIV promoters of CYP19A1 gene through the MAP kinase and JAK/STAT pathway induced by leptin/insulin ligand binding